RESEARCH PAPER
Evaluation of the combined treatment with pregabalin and inhibitors of the renin-angiotensin system against maximal electroshock in mice
 
More details
Hide details
1
Department of Physiopathology, Institute of Rural Health, Lublin, Poland
2
Department of Pathophysiology, Medical University of Lublin, Poland
CORRESPONDING AUTHOR
Krzysztof Łukawski   

Department of Physiopathology, Institute of Rural Health, Lublin, Jaczewskiego 2, 20-090 Lublin, Poland
 
J Pre Clin Clin Res. 2018;12(2):63–66
KEYWORDS
TOPICS
ABSTRACT
Introduction and Objective:
Hypertension is a common comorbid condition in patients with epilepsy. Combined treatment with antiepileptic drugs (AEDs) and antihypertensives may lead to pharmacokinetic and/or pharmacodynamic interactions. The purpose of the current study was to examine the effects of angiotensin-converting enzyme (ACE) inhibitors (captopril and perindopril) and angiotensin AT1 receptor antagonists (losartan and candesartan) on the anticonvulsant activity of pregabalin in the maximal electroshock seizure (MES) test in mice.

Material and methods:
The study was conducted on adult Swiss mice. Drugs were administered intraperitoneally. Electroconvulsions (50 Hz, 500 V, current intensity 25 mA) were produced by a Hugo Sachs generator. Additionally, adverse effects of the combined treatment were assessed in the step-through passive avoidance task and the chimney test.

Results:
. Captopril (50 mg/kg), perindopril (10 mg/kg), losartan (50 mg/kg) and candesartan (8 mg/kg) did not affect the anticonvulsant action of pregabalin in the MES test. In the chimney test, the combinations of pregabalin (315.7 mg/kg) with losartan (50 and 25 mg/kg) significantly impaired motor coordination in mice, P < 0.001 and P < 0.05, respectively. Combinations of pregabalin with other antihypertensives were ineffective in this test. In the passive avoidance task, co-administration of pregabalin with antihypertensives showed a strong tendency towards impaired retention.

Conclusions:
It is suggested that the use of pregabalin with the examined antihypertensive drugs in patients with epilepsy is presumed neutral regarding anticonvulsant action of pregabalin. However, caution is advised during co-administration of pregabalin with losartan at high doses due to neurotoxicity in mice.

 
REFERENCES (28)
1.
Michel MC, Foster C, Brunner HR, Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013; 65(2): 809-848.
 
2.
Regulski M, Regulska K, Stanisz BJ, Murias M, Gieremek P, Wzgarda A, Niznik B. Chemistry and pharmacology of angiotensin-converting enzyme inhibitors. Curr Pharm Des. 2015; 21(13): 1764-1775.
 
3.
Jacob S, Nair AB. An updated overview on therapeutic drug monitoring of recent antiepileptic drugs. Drugs R D. 2016; 16(4): 303-316.
 
4.
Gaitatzis A, Carroll K, Majeed A, Sander JW. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 2004; 45(12): 1613–1622.
 
5.
Löscher W, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 1991; 8(2): 79-94.
 
6.
Sawicka KM, Załuska K, Wawryniuk A, Załuska-Patel K, Szczyrek M, Drop B, Daniluk J, Szpringer M, Żółkowska D, Łuszczki JJ. Ivabradine attenuates the anticonvulsant potency of lamotrigine, but not that of lacosamide, pregabalin and topiramate in the tonic-clonic seizure model in mice. Epilepsy Res. 2017; 133: 67-70.
 
7.
Łukawski K, Janowska A, Jakubus T, Tochman-Gawda A, Czuczwar SJ. Angiotensin AT1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock. Eur J Pharmacol. 2010; 640(1-3): 172-177.
 
8.
Łukawski K, Jakubus T, Raszewski G, Czuczwar SJ. Captopril potentiates the anticonvulsant activity of carbamazepine and lamotrigine in the mouse maximal electroshock seizure model J Neural Transm. 2010; 117(10): 1161-1166.
 
9.
Łukawski K, Raszewski G, Czuczwar SJ. Interactions between levetiracetam and cardiovascular drugs against electroconvulsions in mice. Pharmacol Rep. 2014; 66(6): 1100-1105.
 
10.
Singh N, Sharma G, Singh N, Hanif K. A comparative study of neuroprotective effect of single and combined blockade of AT1 receptor and PARP-1 in focal cerebral ischaemia in rat. Int J Stroke. 2014; 9(5): 560-568.
 
11.
Venault P, Chapouthier G, Prado de Carvalho L, Simiand J, Morre M, Dodd RH, Rossier J Benzodiazepine impairs and β-carboline enhances performance in learning and memory tasks. Nature 1986; 321(6073): 864-866.
 
12.
Boissier JR, Tardy J, Diverres JC. Une nouvelle methode simple pour explorer l’action ‘tranquilisante’: le test de la cheminee. Med Exp. 1960; 3(1): 81-84.
 
13.
Luszczki JJ, Filip D, Czuczwar SJ. Additive interactions of pregabalin with lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves. Epilepsy Res. 2010; 91(2-3): 166-175.
 
14.
Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949; 96(2): 99–113.
 
15.
Łuszczki JJ, Jaskólska A, Dworzański W, Zółkowska D. 7-Nitroindazole, but not NG-nitro-L-arginine, enhances the anticonvulsant activity of pregabalin in the mouse maximal electroshock-induced seizure model. Pharmacol Rep. 2011; 63(1): 169-175.
 
16.
Łukawski K, Janowska A, Jakubus T, Raszewski G, Czuczwar SJ. Combined treatment with gabapentin and drugs affecting the renin-angiotensin system against electroconvulsions in mice. Eur J Pharmacol. 2013; 706(1-3): 92-97.
 
17.
Łukawski K, Janowska A, Czuczwar SJ. Effect of combined treatment with AT1 receptor antagonists and tiagabine on seizures, memory and motor coordination in mice. Adv Clin Exp Med. 2015; 24(4): 565-570.
 
18.
Łukawski K, Raszewski G, Czuczwar SJ. Assessment of combined treatment with vigabatrin and antihypertensive drugs against electroconvulsions in mice. J Pre-Clin Clin Res. 2015; 9(1): 1‒4.
 
19.
Brodie MJ. Antiepileptic drug therapy the story so far. Seizure 2010; 19(10): 650-655.
 
20.
Milić M, Divljaković J, Rallapalli S, van Linn ML, Timić T, Cook JM, Savić MM. The role of α1 and α5 subunit-containing GABAA receptors in motor impairment induced by benzodiazepines in rats. Behav Pharmacol. 2012; 23(2): 191-197.
 
21.
Raghavendra V, Chopra K, Kulkarni SK. Involvement of cholinergic system in losartan-induced facilitation of spatial and short-term working memory. Neuropeptides 1998; 32(5): 417-421.
 
22.
Verma V, Singh N, Singh Jaggi A. Pregabalin in neuropathic pain: evidences and possible mechanisms. Curr Neuropharmacol. 2014; 12(1): 44-56.
 
23.
Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45(Suppl 6): 13-18.
 
24.
Lasoń W, Dudra-Jastrzębska M, Rejdak K, Czuczwar SJ. Basic mechanisms of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update. Pharmacol Rep. 2011; 63(2): 271-292.
 
25.
Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006; 6(1): 108-113.
 
26.
Kaygisiz B, Kilic FS, Senguleroglu N, Baydemir C, Erol K. The antinociceptive effect and mechanisms of action of pregabalin in mice. Pharmacol Rep. 2015; 67(1): 129-133.
 
27.
Luszczki JJ, Wojcik-Cwikla J, Andres MM, Czuczwar SJ. Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology 2005; 30(5): 958-973.
 
28.
Fujihara CK, Velho M, Malheiros DM, Zatz R. An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int. 2005; 67(5): 1913-1924.
 
eISSN:1898-7516
ISSN:1898-2395